TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35296994

Group type: EXPERIMENTAL
Intervention: Sintilimab plus Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sintilimab plus Bevacizumab (7.5 mg/kg dose of Bevacizumab)
Number of subjects: 0
Study: 34319577

Group type: EXPERIMENTAL
Intervention: Tumor assessment frequency under PD-dominant PFS condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor assessment frequency under death-competitive PFS condition
Number of subjects: 0
Study: 32427814

Group type: EXPERIMENTAL
Intervention: RUST system
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: mRUST system
Number of subjects: 45
Study: 35684003

Group type: EXPERIMENTAL
Intervention: Fermented Carica papaya and Morinda citrifolia (28g twice per day for 20 days)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Fermented Carica papaya and Morinda citrifolia
Number of subjects: 188
Study: 32673417

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus (10 mg once a day)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study: 35686365

Group type: EXPERIMENTAL
Intervention: CSE+EM 24 h
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CSE+EM 48 h
Number of subjects: 3

Group type: COMPARATOR
Intervention: CSE
Number of subjects: 3
Study: 33919503

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 0
Study: 32091548

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (2800 IU/d)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Standard-dose vitamin D supplementation (400 IU/d)
Number of subjects: 623
Study: 35040926

Group type: EXPERIMENTAL
Intervention: MedSafer software deprescribing reports
Number of subjects: 5698

Group type: COMPARATOR
Intervention: Usual care (medication reconciliation)
Number of subjects: 5698
Study: 32498561

Group type: EXPERIMENTAL
Intervention: Intensive BP control (Group A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Standard BP control (Group B)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Poor BP control (Group C)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 73
Study: 34059552

Group type: EXPERIMENTAL
Intervention: MRTP claim for heated tobacco products (HTPs), n=1190
Number of subjects: 2354

Group type: COMPARATOR
Intervention: No claim for heated tobacco products (HTPs), n=1164
Number of subjects: 2354
Study: 33361498

Group type: EXPERIMENTAL
Intervention: High frequency meal consumption (six times a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular frequency meal consumption (three times a day)
Number of subjects: 10
Study: 32446880

Group type: EXPERIMENTAL
Intervention: Standard treatment focusing on lifestyle recommendations (ST)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Parent support program without boosters (PGNB)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Parent support program with boosters (PGB)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 174
Study: 34775581

Group type: EXPERIMENTAL
Intervention: Sustained uterine compression (group 1)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Uterine massage (group 2)
Number of subjects: 550
Study: 34647961

Group type: EXPERIMENTAL
Intervention: Active supplement (125 mg L‐lysine, 40 mg vitamin C, 26.3 mg Vitis vinifera extract, 5 mg zinc, 100 mg Citrus aurantium)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Active supplement
Number of subjects: 61
Study: 33009241

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/80 mg FDC
Number of subjects: 42

Group type: COMPARATOR
Intervention: Valsartan 160 mg monotherapy
Number of subjects: 42
Study: 33775867

Group type: EXPERIMENTAL
Intervention: LCMUFA oil (saury oil)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: C20:1 and C22:1 oils
Number of subjects: 60
Study: 33109240

Group type: EXPERIMENTAL
Intervention: Adalimumab (20 mg biweekly if < 30 kg or 40 mg biweekly if ≥ 30 kg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 36171463

Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study: 33407276

Group type: EXPERIMENTAL
Intervention: Beach tennis training (12 weeks, 2 sessions per week lasting 45-60 minutes)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 42
Study: 34214210

Group type: EXPERIMENTAL
Intervention: Perhexiline (150-600 ng/mL)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Perhexiline (therapeutic concentrations)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Perhexiline (supratherapeutic concentrations)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 113
Study: 35404074

Group type: COMPARATOR
Intervention: GST‐HG131 10-300 mg (single ascending dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: GST‐HG131 30-60 mg BID (multiple ascending dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: GST‐HG131 100 mg (multiple ascending dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: GST‐HG131 100 mg (food effect)
Number of subjects: 100
Study: 34426442

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) with ritonavir (cohort 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) with itraconazole (cohort 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 40
Study: 32736164

Group type: EXPERIMENTAL
Intervention: Presence of a caregiver
Number of subjects: 210
Study: 34111245

Group type: EXPERIMENTAL
Intervention: Postexercise recovery in patients with confirmed peripheral neuropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postexercise recovery in patients with subclinical peripheral neuropathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postexercise recovery in healthy controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postexercise recovery in patients with obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitric oxide-dependent function in confirmed peripheral neuropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitric oxide-independent function in confirmed peripheral neuropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurogenic contribution in confirmed peripheral neuropathy
Number of subjects: 0
Study: 35490165

Group type: EXPERIMENTAL
Intervention: JDE exercise program for 12 weeks, twice a week for 45 minutes each
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 59
Study: 33475762

Group type: EXPERIMENTAL
Intervention: Endoscopic enucleation of the prostate (EEP) using plasmakinetic or diode-based techniques
Number of subjects: 458
Study: 35203087

Group type: EXPERIMENTAL
Intervention: Clonidine 4 µg/kg
Number of subjects: 115

Group type: COMPARATOR
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 115
Study: 32614361

Group type: EXPERIMENTAL
Intervention: AqualiefTM (carnosine and dried calyces of Hibiscus sabdariffa L.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35190424

Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS targeted to the affected UE motor map during HABIT sessions
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS to the contralesional motor cortex during HABIT sessions
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham tDCS during HABIT sessions
Number of subjects: 81
Study: 33741216

Group type: EXPERIMENTAL
Intervention: Peer support specialists (PSS)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Facilitated local change team (LCT) intervention
Number of subjects: 680
Study: 34871204

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 0
Study: 36056372

Group type: EXPERIMENTAL
Intervention: Electronic case management with health coaching (ECM+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health coaching alone (HC)
Number of subjects: 0
Study: 34375023

Group type: EXPERIMENTAL
Intervention: Dynamic CCTA (87 patients)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard CCTA (77 patients)
Number of subjects: 164
Study: 33131126

Group type: EXPERIMENTAL
Intervention: Adjuvant allergen immunotherapy (AIT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (non-AIT group)
Number of subjects: 14
Study: 35763249

Group type: EXPERIMENTAL
Intervention: SBRT + Abiraterone acetate 1000 mg and oral prednisone 10 mg daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care (GnRH agonist or antagonist plus abiraterone acetate 1000 mg and oral prednisone 10 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SBRT + Abiraterone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 42
Study: 32693855

Group type: EXPERIMENTAL
Intervention: Monthly nutrition education and counselling (NEC) during pregnancy and infancy period
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 438
Study: 32267032

Group type: EXPERIMENTAL
Intervention: Short intervals (SI: 30-seconds)
Number of subjects: 8
Study: 35295776

Group type: EXPERIMENTAL
Intervention: Optimal pathways to care, education and training program for professionals, systematic screening for children
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific implementation support)
Number of subjects: 20
Study: 32000514

Group type: EXPERIMENTAL
Intervention: Preventive ablation
Number of subjects: 159

Group type: COMPARATOR
Intervention: Deferred ablation
Number of subjects: 159
Study: 34057183

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg bolus at induction, followed by 0.6 μg/kg/h infusion until emergence), n = 75
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo infusion, n = 75
Number of subjects: 369
Study: 34753183

Group type: EXPERIMENTAL
Intervention: Early Intervention (EI) program
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT), Occupational Therapy (OT), Speech Therapy (ST)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Maternal characteristics and state of enrollment
Number of subjects: 818
Study: 32517392

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF)
Number of subjects: 63
Study: 36339169

Group type: EXPERIMENTAL
Intervention: Activity tracker with Personal Activity Intelligence (PAI)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Activity tracker with PAI and access to online training videos (Les Mills+)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Activity tracker with PAI, home-based online training, and additional peer support via social media
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 180
Study: 34259399

Group type: EXPERIMENTAL
Intervention: Yin-yang penetrating acupuncture with elongated needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study: 32779001

Group type: EXPERIMENTAL
Intervention: β1 + 2 AR antagonist (nadolol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: β1 AR antagonist (bisoprolol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 35569763

Group type: EXPERIMENTAL
Intervention: Intravitreal 1.0 mg risuteganib
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 39
Study: 33707988

Group type: EXPERIMENTAL
Intervention: 30 s × 3 times
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30 s × 10 times
Number of subjects: 45

Group type: COMPARATOR
Intervention: 30 s × 1 time
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 32883371

Group type: EXPERIMENTAL
Intervention: Ibuprofen alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen in combination with acetaminophen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen in combination with hydromorphone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen alone, Ibuprofen + Acetaminophen, Ibuprofen + Hydromorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Opioid trial
Number of subjects: 0
Study: 32186924

Group type: EXPERIMENTAL
Intervention: Mothers and Babies Course (a six-week Spanish cognitive behavioural therapy group intervention)
Number of subjects: 86
Study: 36278293

Group type: EXPERIMENTAL
Intervention: Test formulation (Zhejiang Xianju Pharmaceutical Co., Ltd., China)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Reference formulation (Medrol, Pfizer Italia SRL)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 56
Study: 33113088

Group type: EXPERIMENTAL
Intervention: Concurrent trastuzumab and chemotherapy
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Sequential trastuzumab after chemotherapy
Number of subjects: 1843
Study: 32998696

Group type: EXPERIMENTAL
Intervention: lncRNA expression analysis during HFs cycle
Number of subjects: 2884

Group type: EXPERIMENTAL
Intervention: GO and KEGG enrichment analysis of DELs
Number of subjects: 2884

Group type: EXPERIMENTAL
Intervention: Comparative analysis of DELs with cashmere goat lncRNA-seq data
Number of subjects: 2884
Study: 35564330

Group type: EXPERIMENTAL
Intervention: Satir Transformational Systemic Therapy (STST) group counseling intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control/no treatment
Number of subjects: 60
Study: 34639313

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation with VAPA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 34759287

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 112
Study: 32571334

Group type: EXPERIMENTAL
Intervention: Healthy diets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unhealthy diets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food costs
Number of subjects: 0
Study: 35956281

Group type: EXPERIMENTAL
Intervention: Early introduction of solid foods (10‐12th week corrected age)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Late introduction of solid foods (16‐18th week corrected age)
Number of subjects: 177
Study: 34339686

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 0
Study: 36498087

Group type: EXPERIMENTAL
Intervention: Abdominal wall block (AWB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: General anesthesia (Control group)
Number of subjects: 64
Study: 33582295

Group type: EXPERIMENTAL
Intervention: Mobile mental health platform
Number of subjects: 7884

Group type: COMPARATOR
Intervention: Referral to usual care
Number of subjects: 7884
Study: 32456236

Group type: EXPERIMENTAL
Intervention: Dietary intervention consisting of green vegetables, beef, whole milk, and butter for 6 months.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard care (no treatment) as control group.
Number of subjects: 62
Study: 35109960

Group type: EXPERIMENTAL
Intervention: Montmorency cherries (30 ml twice daily)
Number of subjects: 50
Study: 34558312

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 112

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 112
Study: 35672660

Group type: EXPERIMENTAL
Intervention: DexP group (60 µg of dexmedetomidine added to ropivacaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DexIV group (systemic-only dexmedetomidine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal saline as a placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DexP and DexIV groups
Number of subjects: 60
Study: 33208662

Group type: EXPERIMENTAL
Intervention: Elasticized longitudinal stockinette (ELS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Elasticized tubular bandage (ETB)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both ELS and ETB
Number of subjects: 25
Study: 34569482

Group type: EXPERIMENTAL
Intervention: Molidustat (25 mg or 50 mg once daily)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Darbepoetin (darbepoetin alfa, injected subcutaneously once every 2 or 4 weeks)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 164

Group type: COMPARATOR
Intervention: Darbepoetin
Number of subjects: 164
Study: 32398710

Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 174
Study: 37420186

Group type: EXPERIMENTAL
Intervention: 7 days of oestrogen priming (group A)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 14 days of oestrogen priming (group B)
Number of subjects: 144
Study: 34446477

Group type: EXPERIMENTAL
Intervention: Digital diabetes prevention intervention (mobile app)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mobile app (beta testing)
Number of subjects: 100
Study: 32067633

Group type: EXPERIMENTAL
Intervention: Azithromycin (∼20 mg/kg)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 35907825

Group type: EXPERIMENTAL
Intervention: Modified paramedian technique (group PM)
Number of subjects: 150
Study: 34292493

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (100 U)
Number of subjects: 248

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 248
Study: 32825595

Group type: EXPERIMENTAL
Intervention: Combined fitness training
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (cessation of training)
Number of subjects: 113
Study: 36326604

Group type: EXPERIMENTAL
Intervention: Dapagliflozin, 10 mg per day
Number of subjects: 6262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6262
Study: 32938561

Group type: EXPERIMENTAL
Intervention: Presence of comorbidities (evaluated using the updated Charlson comorbidity index)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Patients with congestive heart failure
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Patients with dementia
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Patients with hemiplegia/paraplegia
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Patients with renal disease
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tumor grade
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Updated Charlson comorbidity index
Number of subjects: 136
Study: 32951241

Group type: EXPERIMENTAL
Intervention: Pre-mixed nitrous oxide/oxygen mixture treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Medical air treatment
Number of subjects: 200
Study: 35709798

Group type: COMPARATOR
Intervention: Unadjuvanted PXVX0317 (2×20 μg)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×6 μg)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×10 μg)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×20 μg)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×6 μg, accelerated)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×10 μg, accelerated)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×20 μg, accelerated)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (1×40 μg)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×20 μg + booster 40 μg)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (various doses)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Unadjuvanted PXVX0317
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 415
Study: 33860972

Group type: EXPERIMENTAL
Intervention: Video-based advance care planning intervention (5-min video)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 82
Study: 35302207

Group type: EXPERIMENTAL
Intervention: Ciprofol 0.4 mg/kg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Propofol 2.0 mg/kg
Number of subjects: 176
Study: 33580595

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (1,000 mg for 8 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (methyl cellulose)
Number of subjects: 71
Study: 32167393

Group type: EXPERIMENTAL
Intervention: Idasanutlin + cytarabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + cytarabine
Number of subjects: 0
Study: 33340674

Group type: EXPERIMENTAL
Intervention: NO3−‐rich beetroot powder (5 g/d contains 250 mg NO3−)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 32365613

Group type: EXPERIMENTAL
Intervention: Multi-system Physical Exercise (MPE) group, n = 36
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group, n = 36
Number of subjects: 72
Study: 35064330

Group type: EXPERIMENTAL
Intervention: 3D head‐mounted (HMD) virtual reality (VR)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2D screen applications
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison between 3D HMD VR and 2D screen applications
Number of subjects: 13
Study: 34810362

Group type: EXPERIMENTAL
Intervention: Photofunctionalization (PF group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (standard tapered root form implant without pretreatment)
Number of subjects: 90